載入中
Ernexa Therapeutics Inc. is a biotechnology firm currently in its preclinical development phase, specializing in the creation of therapeutic interventions using induced mesenchymal stem cells (iMSCs). The company's primary focus lies in addressing solid tumor cancers and a range of autoimmune diseases. Its flagship candidate, ERNA-101, is an allogeneic iMSC designed to release pro-inflammatory cytokines, namely IL-7 and IL-15, intended for the treatment of ovarian cancer. Additionally, Ernexa is developing ERNA-102, an iMSC product engineered to secrete the anti-inflammatory cytokine IL-10, aimed at managing rheumatoid arthritis. The company has a licensing arrangement in place with Factor Bioscience Limited. Established in 2018, this Cambridge, Massachusetts-based entity operated as Eterna Therapeutics Inc. until its rebranding to Ernexa Therapeutics in March 2025.
前收盤價
US$2.40
−US$0.09 · -3.61%
Ernexa Therapeutics Inc. is a biotechnology firm currently in its preclinical development phase, specializing in the creation of therapeutic interventions using induced mesenchymal stem cells (iMSCs). The company's primary focus lies in addressing solid tumor cancers and a range of autoimmune diseases. Its flagship candidate, ERNA-101, is an allogeneic iMSC designed to release pro-inflammatory cytokines, namely IL-7 and IL-15, intended for the treatment of ovarian cancer. Additionally, Ernexa is developing ERNA-102, an iMSC product engineered to secrete the anti-inflammatory cytokine IL-10, aimed at managing rheumatoid arthritis. The company has a licensing arrangement in place with Factor Bioscience Limited. Established in 2018, this Cambridge, Massachusetts-based entity operated as Eterna Therapeutics Inc. until its rebranding to Ernexa Therapeutics in March 2025.
日內區間
目前US$2.40
52週區間
目前US$2.40
Ernexa Therapeutics Inc. is a biotechnology firm currently in its preclinical development phase, specializing in the creation of therapeutic interventions using induced mesenchymal stem cells (iMSCs). The company's primary focus lies in addressing solid tumor cancers and a range of autoimmune diseases. Its flagship candidate, ERNA-101, is an allogeneic iMSC designed to release pro-inflammatory cytokines, namely IL-7 and IL-15, intended for the treatment of ovarian cancer. Additionally, Ernexa is developing ERNA-102, an iMSC product engineered to secrete the anti-inflammatory cytokine IL-10, aimed at managing rheumatoid arthritis. The company has a licensing arrangement in place with Factor Bioscience Limited. Established in 2018, this Cambridge, Massachusetts-based entity operated as Eterna Therapeutics Inc. until its rebranding to Ernexa Therapeutics in March 2025.
日內區間
目前US$2.40
52週區間
目前US$2.40
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | — | 58.2萬 USD | 6.8萬 USD | — | — |
| 銷貨成本 | — | 9.6萬 USD | 23.6萬 USD | — | — |
| 毛利 | — | 48.6萬 USD | −16.8萬 USD | — | — |
| 研究與開發 | 415.6萬 USD | 460.4萬 USD | 592萬 USD | 1039.2萬 USD | 1270.5萬 USD |
| 銷售、一般及管理費用 | 516.3萬 USD | 1313.2萬 USD | 1458.6萬 USD | 1655.5萬 USD | 1472.4萬 USD |
| 營業費用 | 931.9萬 USD | 1616萬 USD | 2096.7萬 USD | 3321.7萬 USD | 1.14億 USD |
| 利息收入 | 8.3萬 USD | 24.9萬 USD | 13.8萬 USD | — | — |
| 利息支出 | 2.7萬 USD | 675.2萬 USD | 61.4萬 USD | 3萬 USD | 7.4萬 USD |
| 折舊和攤銷 | 26.3萬 USD | 163.8萬 USD | 112.3萬 USD | 49.7萬 USD | 45.9萬 USD |
| 營業利益 | −931.9萬 USD | −1567.4萬 USD | −2113.5萬 USD | −3321.7萬 USD | −1.14億 USD |
| 淨利 | −1408.4萬 USD | −4453.9萬 USD | −2166.8萬 USD | −2457.9萬 USD | −1.23億 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2026年5月4日 | 1:25 | — | — |
股票分割 | 2025年6月12日 | 1:15 | — | — |
股票分割 | 2022年10月17日 | 1:20 | — | — |
股票分割 | 2021年3月26日 | 1:2 | — | — |
股票分割 | 2016年6月17日 | 1:50 | — | — |
已生效 2026年5月4日
1:25
已生效 2025年6月12日
1:15
已生效 2022年10月17日
1:20
已生效 2021年3月26日
1:2
已生效 2016年6月17日
1:50
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
